MTDH antibody (AA 101-270)

Catalog No. ABIN3031760

The Rabbit Polyclonal anti-MTDH antibody is suitable to detect MTDH in samples from Human, Mouse and Rat. It has been validated for WB, ICC and IHC (p).

Quick Overview for MTDH antibody (AA 101-270) (ABIN3031760)

Target: MTDH (Metadherin (MTDH))

Reactivity: Human, Mouse, Rat

Host: Rabbit

Clonality: Polyclonal

Conjugate: This MTDH antibody is un-conjugated

Application: Western Blotting (WB), Immunocytochemistry (ICC), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Product Details anti-MTDH Antibody

Binding Specificity: AA 101-270

Purpose: LYRIC Antibody / Metadherin / AEG-1

Purification: Antigen affinity

Immunogen: Human partial recombinant protein (AA 101-270) was used as the immunogen for this LYRIC antibody.

Isotype: IgG

Application Details

Application Notes: The stated application concentrations are suggested starting amounts. Titration of the LYRIC antibody may be required due to differences in protocols and secondary/substrate sensitivity.

Restrictions: For Research Use only

Handling

Format: Lyophilized

Buffer: 0.5 mg/mL if reconstituted with 0.2 mL sterile DI water

Storage: 4 °C,-20 °C

Storage Comment: After reconstitution, the LYRIC antibody can be stored for up to one month at 4oC. For long-term, aliquot and store at -20oC. Avoid repeated freezing and thawing.

Target Details for MTDH

Target: MTDH (Metadherin (MTDH))

Alternative Name: LYRIC

Background: MTDH (Metadherin), also known as LYRIC or astrocyte elevated gene-1 protein (AEG-1), is a protein that in humans is encoded by the MTDH gene. It is involved in HIF-1 alpha mediated angiogenesis, interacts with SND1 and is involved in RNA-induced silencing complex (RISC), and plays a very important role in RISC and miRNA functions. LYRIC induces an oncogene called Late SV40 factor (LSF/TFCP2) which is involved in thymidylate synthase (TS) induction and DNA biosynthesis synthesis. Late SV40 factor enhances angiogenesis by transcriptionally up-regulating matrix metalloproteinase-9 (MMP9). LYRIC acts as an oncogene in melanoma, malignant glioma, breast cancer and hepatocellular carcinoma. It is highly expressed in these cancers and helps in progression and development of these cancers. It is induced by c-Myc oncogene and plays very important role in anchorage independent growth of cancer cells.

Pathways: Cellular Response to Molecule of Bacterial Origin, Cell-Cell Junction Organization